Press & Media

About Fanconi Anemia and FCF

Fanconi anemia (known as FA) is a genetic DNA repair disease that can affect every system of the body. In people with FA, cells have less ability to repair themselves and as a result, errors in these cells will increase over time, causing cancer and often bone marrow failure. The Fanconi Cancer Foundation (FCF) is the leading organization worldwide dedicated to curing this disease. Our mission is to improve the lives of people affected by Fanconi anemia and associated cancers worldwide by funding exceptional research and empowering our community.

Media Contacts

For media inquiries, please reach out to:
Sherri Van Ravenhorst, Communications Director
Email: sherri@fanconi.org

Media Resources

Access our collection of media resources to support your coverage of the Fanconi Cancer Foundation:

Are you an FA community member looking to share your story with the media? We can help!

Testimonials and Impact Stories

Read inspiring quotes and stories from families and leaders that highlight the impact of our work.

The Latest

News & Events

2025 Research Updates

Research is the answer to one day making FA a treatable, manageable disease. Here, you'll discover the most recent strides in FA research and activities funded by FCF. Every quarter, we'll bring you updates on newly funded grants, ongoing projects, and significant milestones.

Read More >

Global Community, Shared Discovery: 2025 Symposium and Adult Retreat Bring FA Collaboration to Life

Nearly 300 members of the global Fanconi anemia community gathered in Minneapolis for the 2025 Scientific Symposium and Retreat for Adults with FA, three days that blended science, lived experience, and hope.

Read More >

Phil and Penny Knight’s $10 Million, Decade-Long Gift Transforms Rare Disease and Cancer Research

Research supported by the Knights has shaped best practices in prevention, early-detection, and treatment strategies for cancer, benefiting people with FA and providing far-reaching benefits for the broader population.

Read More >